Table 4.
Unadjusted and Adjusted Estimates of Patients' Outcome According to Drug Regimen
| Outcome End Point | P | TT, n (%) | DAPT, n (%) | VKA/C, n (%) |
|---|---|---|---|---|
| Overall survival | ||||
| 1 month | 656 (96.6) | 155 (95.7) | 72 (100) | |
| 6 month | 621 (91.5) | 148 (92.0) | 70 (95.9) | |
| 12 month | 604 (89.0) | 144 (88.9) | 68 (93.2) | |
| Log rank | 0.527 | |||
| CHADS2 adjusted | 0.516 | |||
| DES adjusted | 0.575 | |||
| Propensity score adjusted | 0.561 | |||
| Freedom from myocardial infarction | ||||
| 1 month | 650 (99.1) | 150 (96.8) | 72 (98.6) | |
| 6 month | 600 (96.3) | 141 (94.2) | 67 (95.8) | |
| 12 month | 560 (92.2) | 137 (93.5) | 65 (94.4) | |
| Log rank | 0.170 | |||
| CHADS2 adjusted | 0.223 | |||
| DES adjusted | 0.168 | |||
| Propensity score adjusted | 0.247 | |||
| Freedom from repeat revascularization | ||||
| 1 month | 653 (99.4) | 155 (96.9) | 71 (97.3) | |
| 6 month | 625 (98.7) | 149 (96.3) | 66 (93.1) | |
| 12 month | 585 (94.2) | 145 (95.0) | 63 (90.2) | |
| Log rank | 0.691 | |||
| CHADS2 adjusted | 0.755 | |||
| DES adjusted | 0.660 | |||
| Propensity score adjusted | 0.218 | |||
| Freedom from stent thrombosis | ||||
| 1 month | 653 (99.4) | 154 (99.4) | 72 (100) | |
| 6 month | 616 (99.1) | 146 (98.1) | 68 (97.2) | |
| 12 month | 598 (98.6) | 141 (98.1) | 66 (97.2) | |
| Log rank | 0.618 | |||
| CHADS2 adjusted | 0.598 | |||
| DES adjusted | 0.609 | |||
| Propensity score adjusted | 0.971 | |||
| Freedom from stroke/TIA | ||||
| 1 month | 655 (99.7) | 153 (98.1) | 72 (100) | |
| 6 month | 619 (99.2) | 146 (96.8) | 70 (100) | |
| 12 month | 596 (97.9) | 140 (95.5) | 67 (98.5) | |
| Log rank | 0.192 | |||
| CHADS2 adjusted | 0.156 | |||
| DES adjusted | 0.176 | |||
| Propensity score adjusted | 0.442 | |||
| Freedom from BARC >1 bleedings | ||||
| 1 month | 590 (93.7) | 131 (92.8) | 66 (95.8) | |
| 6 month | 542 (90.8) | 117 (87.7) | 60 (95.8) | |
| 12 month | 515 (89.4) | 112 (86.2) | 56 (92.5) | |
| Log rank | 0.563 | |||
| CHADS2 adjusted | 0.332 | |||
| DES adjusted | 0.447 | |||
| Propensity score adjusted | 0.342 | |||
| Freedom from MACCE | ||||
| 1 month | 642 (93.9) | 147 (90.7) | 69 (94.5) | |
| 6 month | 587 (86.6) | 135 (83.3) | 63 (86.3) | |
| 12 month | 538 (79.4) | 129 (79.6) | 60 (82.2) | |
| Log rank | 0.775 | |||
| CHADS2 adjusted | 0.753 | |||
| DES adjusted | 0.847 | |||
| Propensity score adjusted | 0.745 |
Abbreviations: BARC, Bleeding Academic Research Consortium; DAPT, dual antiplatelet therapy; DES, drug‐eluting stent; MACCE, major adverse cardiac/cerebrovascular events; TT, triple therapy; VKA, vitamin K antagonist; VKA/C, vitamin K antagonist plus clopidogrel.
Data are reported as number of patients at risk entering the study intervals (percentage).